

**CPDD EXECUTIVE COMMITTEE**

**President**  
William Stoops, Ph.D.

**President-Elect**  
Amy Janes, Ph.D.

**Treasurer**  
Jack Bergman, Ph.D.

**Past-President**  
Stacey Sigmon, Ph.D.

**Public Policy Officer**  
Sandra Comer, Ph.D.

**CPDD BOARD OF DIRECTORS**

Sudie Back, Ph.D.
Qiana Brown, Ph.D.
F. Ivy Carroll, Ph.D.
Ziva Cooper, Ph.D.
Kelly Dunn, Ph.D.
Albert Garcia-Romeu, Ph.D.
Deborah Hasin, Ph.D.
Angela Heads, Ph.D.
Amy Janes, Ph.D.
Jermaine Jones, Ph.D.
Frances Levin, M.D.
Wendy Lynch, Ph.D.
Marco Pravetoni, Ph.D.
James Rowlett, Ph.D.
Dace Svikis, Ph.D.
Michael Taffe, Ph.D.
Erin Winstanley, Ph.D.

**CPDD EX OFFICIO**

**Rules Chair**  
Charles Gorodetzky, M.D., Ph.D.

**Executive Officer**  
Jesse Howard

**EDITORS**  
Maria Parker, M.P.H., M.S., Ph.D.

**CPDD COMMUNICATIONS COMMITTEE**

Annie Kleykamp, Ph.D., Chair  
Liz Evans, M.A., Ph.D.
Lindsey Hammerslag, Ph.D.
Jillian Hardee, Ph.D.
Lynn Kirby, Ph.D.
Gregory Miller, Ph.D.
Barrett Mongomery, Ph.D.
Jacques Nguyen, Ph.D.
Joseph Palamar, Ph.D.
Maria Parker, Ph.D., M.P.H., M.S.
Tasha Perdue, Ph.D.
Irene Pericot-Valverde, Ph.D.
Jonathan Stoltman, Ph.D.

Want to contribute or advertise in Newsline? Email info@cpdd.org.
Dear CPDD friends and colleagues,

As CPDD enters its 93rd year, I am thrilled and honored to serve the organization as its President. For nearly two years, we have endured the Coronavirus pandemic. Although I have so missed getting to be with all of you at our last two scientific meetings, I am hopeful and confident that we can be together at our 84th CPDD meeting in Minneapolis where we can again learn about the top addiction science being conducted in our field in person!

I want to express my deep admiration and appreciation for our outgoing President, Dr. Stacey Sigmon. Stacey spent many hours working with the CPDD Executive Committee, Board of Directors, Committee Chairs, and our PMG team to ensure our organization continued to thrive in the face of adversity. Thanks to her efforts, along with our Treasurer Dr. Jack Bergman and the CPDD Finance Committee, the College did not have to dip into our investments like we have had to do in previous years. Under Stacey’s leadership, new initiatives were started like the Early Career Member Poster Award and webinars on timely substance use research topics. These will continue into the years to come.

The CPDD Program Committee deserves much credit for how successful 2021 has been for us. Thanks to the leadership of Dr. Kelly Dunn, CPDD expanded its virtual meeting opportunities and created a highly cohesive program that was highly praised by attendees. Their commitment to ensuring our meeting’s success was pivotal so I want to convey my deepest appreciation to Kelly and her team.

As might be surmised from my comments above, the CPDD Executive Committee, Program Committee led by Dr. Dunn and Dr. Kevin Freeman (Program Committee Chair-Elect), Board of Directors, and PMG team has already been hard at work planning for the 84th Annual Scientific Meeting June 11-15, 2022, in Minneapolis, MN. We welcome and highly encourage members to share their feedback, suggestions, and travel plans. Specifically, if you attend any face-to-face meetings before CPDD, do not hesitate to get in touch with our team at info@cpdd.org with ideas or examples of what worked well for other organizations. As of now, CPDD plans to be in Minneapolis but will have digital components for those wishing to participate online.

While 2021 wasn’t the year we all planned, I’m very proud of the CPDD community and all of our substance use disorder research efforts. We continue to advocate for research because our work is more critical than ever. Since becoming President, I’ve been so impressed to see the breadth, depth and passion of our advocacy efforts on behalf of the substance use research community, as well as those affected by substance use disorder. If you’re interested in becoming involved in CPDD’s advocacy efforts, please let me know by emailing me at william.stoops@uky.edu. I look forward to seeing each of you at next year’s meeting and hearing from you this year as your President. Please do not hesitate to reach out if you’ve got questions, comments or ideas to make CPDD an even stronger organization!

Best regards,

Bill Stoops, PhD
CPDD President
CPDD BOARD OF DIRECTORS AND PRESIDENT-ELECT NOMINATIONS NOW OPEN

Nominate members for President-Elect and the Board of Directors through Friday, October 29.

NOMINATE NOW
The College on Problems of Drug Dependence (CPDD) is excited to announce that Dr. Cassandra Gipson-Reichardt, PhD, has been awarded the 2021 Joseph Cochin Young Investigator Award for Excellence.

The Cochin Award, in memory of a respected leader in drug abuse research and a former Chairman and Executive Secretary of CPDD, was established in 1986 to recognize research contributions in any facet of the field of substance use disorder. Given annually to an investigator who has demonstrated excellence in their field of research, authored several publications, and not attained their 40th birthday by July 1st in the year of the award, the Cochin Award is one of CPDDs most prestigious awards to receive.

Dr. Cassandra Gipson-Reichardt is a preclinical addiction neuroscientist, focusing on glutamatergic, cholinergic, ovarian hormone, and neuroimmune mechanisms involved in nicotine use and opioid/stimulant polysubstance use using rodent models. Upon receiving her award Dr. Gipson-Reichardt stated, "I am so grateful to receive the Cochin award this year. This award is meaningful to me because my colleagues, mentors, family, and friends have contributed so much to my career. To be recognized in this way truly is wonderful, and it is a reflection of the support I have received."

The Joseph Cochin Young Investigator Award was the only Award for Excellence given by The College on Problems of Drug Dependence in 2021. All other awards will resume in 2022. For more information on the CPDD 83rd Annual Scientific Virtual Meeting, visit https://cpdd.org/meetings/current-meeting/.

The association between child alcohol sipping and alcohol expectancies in the ABCD study
Mikela A. Murphy, Steven C. Dufour, Joshua C. Gray
Underage drinking is a serious public health concern, yet relatively little is known about how child sipping of alcohol relates to favorable beliefs about the effects of alcohol (i.e., alcohol expectancies). This study examined the association between sipping and alcohol expectancies utilizing data from the Adolescent Brain Cognitive Development study. Children who had sipped alcohol (22% of the sample) had more positive alcohol expectancies than children who had not sipped alcohol. These findings indicate that child sipping may play a unique role in the development and maintenance of alcohol expectancies, which have known associations with later problematic drinking behavior.

Cannabis use in college: Genetic predispositions, peers, and activity participation
Nathaniel S. Thomas, Jessica E. Salvatore, Nathan A. Gillespie, Fazil Aliev, Albert J. Ksinan, Danielle M. Dick, Spit for Science Working Group
Cannabis use among college students is associated with health, memory, and academic problems. Some individuals are genetically more at risk of using cannabis, but genes are not destiny. The environment can change the likelihood that an at-risk person will develop problems. In this study, we tested whether the impact of genetic risk factors for cannabis use varied as a function of social activity participation and peer influences. We found that genetic risk for cannabis use was most influential among students who reported never engaging with community activities, such as volunteer organizations or interest groups.
2021 Travel Award recipients received complimentary registration to the 2021 Virtual Meeting and are eligible to apply for the same award in the future (excludes Holtzman and Primm-Singleton).

**7th Annual Steve G. Holtzman Travel Award for Preclinical Investigators**
- Fernando de Moura, Ph.D., Harvard Medical School/McLean Hospital
- Gayatri Bhatia, M.D., All India Institute of Medical Sciences
- Anees Bahji, B.Sc., M.D., University of Calgary
- Afolabi Oyapero, M.P.H., Lagos State University College of Medicine
- Suzaily Wahab, Dr. (Psych), University Kebangsaan Malaysia Medical Centre

**CPDD International Award**
- Laura Brandt, Ph.D., Columbia University Irving Medical Center and New York State Psychiatric Institute
- Irene Pericot-Valverde, Ph.D., Clemson University

**FORCE Award**
- Laura Brandt, Ph.D., Columbia University Irving Medical Center and New York State Psychiatric Institute
- Irene Pericot-Valverde, Ph.D., Clemson University

**Primm-Singleton Minority Travel Award**
- Emmanuel Alvarez, B.S., Rutgers Robert Wood Johnson Medical School
- Mehreen Arif, M.P.H., State University of New York at Buffalo
- Bryan Benitez, M.A., Yale University School of Medicine
- Whitney Cordoba-Grueso, M.D., M.P.H., Indiana University
- Coralie Perez-Pedrogo, Ph.D., University of Puerto Rico, Medical Sciences Campus and Albu University
- Edda Rodriguez, M.P.H., Miller School of Medicine, University of Miami

**CPDD Early Career Investigator Awards**
- Gemma Aonso-Diego, M.A., University of Oviedo, Addictive Behaviors Group
- Amelia Bailey, B.A., University of Massachusetts
- Emmanuelle Baillot, M.Sc., University of Bordeaux
- Patrick Brown, B.S., Oregon Health and Science University
- Katina Calakos, Ph.D., Yale University
- Sierra Castedo de Martell, M.P.H., UTHealth School of Public Health
- Nina Christie, M.A., University of Southern California
- Sarah Clingan, Ph.D., University of California, Los Angeles
- William Craft, B.S., Fralin Biomedical Research Institute at Virginia Tech Carilion
- Morgan Crowley, B.S., University of Florida
- Ayomide David, B.Sc., University of Florida
- Graham DiGuiseppi, M.Sc., University of Southern California
- Julien Dodu, B.Sc., Virginia Commonwealth University
- Dalton Edwards, M.S., University of Texas at Dallas
- Andrew Fares, B.Sc., Centre for Addiction and Mental Health
- Ze Fei, Ph.D., University of California, Los Angeles
- David Fink, Ph.D., New York State Psychiatric Institute
- Ewa Galaj, Ph.D., NIDA IRP
- Erik Garcia, Ph.D., University of Texas Medical Branch
- Grant Glatfelter, Ph.D., NIDA Intramural Research Program
- Rachel Hoopsick, Ph.D., State University of New York at Buffalo
- Jennifer Hoots, M.A., University of Illinois At Chicago
- Erin Horne, Ph.D., University of Texas at Dallas
- Raagini Jawa, Med.D.Sc., Boston Medical Center
- Bernard Johnson, M.S., Wake Forest School of Medicine, Department of Physiology and Pharmacology
- Arian Johnson, M.P.H., Student
- Luisa Kcomt, Ph.D., University of Michigan
- Shailesh Khatri, Ph.D., University of Kentucky
- Emanuel Krebs, M.A., Faculty of Health Sciences, Simon Fraser University
- Jessica Kulak, M.P.H., M.S., Ph.D., Buffalo State College
- Pooja Lagisetty, M.D., University of Michigan
- Laura Lambert, M.Sc., University of Bordeaux
- Jihan Lee, Ph.D., Yale University School of Medicine
- Huajun Liang, D.Phil., University of Maryland
- Kelsey Lucerne, B.S., Icahn School of Medicine At Mount Sinai
- Sarah Lynn, M.S., Virginia Tech
- Daniel Martins, M.Sc., University of Porto
CPDD Early Career Investigator Awards (Continued)

- Kristen McLaurin, Ph.D., University of South Carolina
- Christina Merritt, B.S., University of Texas Medical Branch
- Barrett Montgomery, B.S., Michigan State University
- Catherine Moore, Ph.D., Johns Hopkins University School of Medicine
- Lauren Nguyen, B.A., University of Washington
- Stephanie Parent, M.P.H., Queen's University Faculty of Medicine

- Emily Peck, B.S., Wake Forest School of Medicine
- Daria Piacentino, M.D., National Institute of Drug Abuse/NIH/DHHS

- Stephen Robertson, Ph.D., University of Michigan
- Kelly Sagar, Ph.D., McLean Hospital, Harvard Medical School

- Karl Schmidt, Ph.D., Davidson College
- Paige Shaffer, M.P.H., University of Massachusetts Medical School

- Vinita Sharma, M.P.H., Ph.D., University of Florida
- Jessica Sharp, D.Phil., Davidson College

- Justin Shepherd, M.A., University of Houston
- Kelsey Simpson, M.A., University of Southern California

- Ashley Smith, Ph.D., University of Texas Medical Branch
- Kyle Snyder, B.S., M.P.H., New York University School of Global Public Health

- Ryan Sullivan, M.S., University of Wisconsin-Milwaukee
- Forrest Toegel, Ph.D., Johns Hopkins University School of Medicine

- Devin Tomlinson, B.S., Fralin Biomedical Research Institute at VTC
- Richa Tripathi, Dr. Med. Sc., M.D., All India Institute of Medical Sciences

- Helena Valente, B.Sc., Porto University
- Alyssa Vanderziel, M.S., Michigan State University College of Human Medicine

- Kainan Wang, Ph.D., McLean Hospital, Harvard Medical School
- Heather Ward, M.D., Beth Israel Deaconess Medical Center/Harvard Medical School

- Rhiannon Wiley, B.A., University of Vermont

NIDA Directors Travel Awards

- Erin Martin, B.A., Medical University of South Carolina
- Victor Martinez-Loredo, Ph.D., University of Zaragoza
- Hannah Mayberry, B.S., Temple University
- Elisa Pabon, B.S., The University of Chicago

- Jobe Ritchie, B.S., Washington State University
- Pedro Rodriguez-Rivera, M.P.H., University of Maryland School of Medicine

- Joy Scheidell, M.P.H., Ph.D., New York University Grossman School of Medicine
- Drew Townsend, Ph.D., Virginia Commonwealth University

NIDA Women & Sex/Gender Junior Investigator Travel Awards

- Janna Ataiants, Dr. P.H., Drexel University Dornsife School of Public Health
- Elizabeth Charron, M.P.H., M.S., Ph.D., University of Utah

- Alba Gonzalez-Roz, Ph.D., Department of Psychology/IUNICS/University of the Balearic Islands
- Erin Maher, Ph.D., University of Kentucky

- Angel Algarin, M.P.H., Ph.D., University of California San Diego
- Trent Bullock, M.A., Lewis Katz School of Medicine at Temple University

- Danielle Davis, Ph.D., Yale University School of Medicine
- Teresa DeAtley, M.P.H., Brown University School of Public Health

- Michelle Doyle, B.S., University of Texas Health Science Center at San Antonio
- Alice Ely, Ph.D., Perelman School of Medicine University of Pennsylvania

- Nicole FitzGerald, B.A., University of Florida
- Brianna George, B.A., Wake Forest School of Medicine

- Priscila Goncalves, Ph.D., Columbia University
- Sarah Gutkind, M.S., Columbia University

- Zachary Mannes, M.P.H., Ph.D., Columbia University, Mailman School of Public Health
- Nathaniel Moxley-Kelly, M.Sc., University of Vermont

- Alexandra Palmisano, Ph.D., Yale University School of Medicine
- Justin Strickland, Ph.D., Johns Hopkins University School of Medicine

- Andre B. Toussaint, M.A., Temple University
- Neil Varshneya, B.S., M.S., Ph.D., Johns Hopkins University School of Medicine

- Noel Vest, Ph.D., Stanford University School of Medicine
- Alison Wakeford, Ph.D., Harvard Medical School McLean Hospital

- Heather Webber, Ph.D., University of Texas Health Science Center
The Canadian Society of Addiction Medicine’s 2021 Scientific Conference is Canada’s premier online education and networking event for addiction medicine practitioners. Visit our website to learn more and register today!

CSAMconference.org
The opioid overdose crisis has received considerable attention since the beginning of the 21st century, and while the current (third-wave) crisis is fueled largely by synthetic opioids like fentanyl, oxycodone is still among the most prescribed opioid analgesics for the treatment of pain. Unfortunately, those who misuse oxycodone or other prescription opioids are at an increased risk of transitioning to illicit opioid use, particularly when their prescription has ended and/or during periods of withdrawal. Surprisingly few preclinical researchers have evaluated neurobiological mechanisms underlying key features of addiction with oxycodone, including escalation of drug intake, the development of physical dependence, and withdrawal. This is one area of focus in the laboratory of Dr. Jacques Nguyen, Ph.D. Currently, Dr. Nguyen is an Assistant Project Scientist in the Department of Psychiatry at the University of California San Diego in La Jolla, California. Dr. Nguyen was recently awarded a K99/R00 Award from the National Institute on Drug Abuse (NIDA) to elucidate behavior and neural circuits underlying opioid addiction and dependence, and this award has already produced important results. In a recent publication (Nguyen et al. 2021, British Pharmacological Society), Dr. Nguyen and his colleagues used Wistar rats in intracranial self-stimulation (ICSS), a procedure in which an animal responds on an operant manipulandum (e.g. quarter turn of a wheel) to receive pulses of electrical brain stimulation to a brain region of interest, often in the medial forebrain bundle, and ICSS thresholds can be obtained. When ICSS thresholds are lowered, this reflects a facilitation of brain stimulation reward, and acute administration of drugs of abuse, like oxycodone, lower ICSS thresholds. When ICSS thresholds are elevated, this reflects reduced or diminished reward. Elevated thresholds occur following activation of kappa-opioid receptors and during withdrawal from chronic opioid administration. In addition to their ICSS procedure, Dr. Nguyen and his colleagues used intravenous oxycodone self-administration to investigate potential affective consequences (via ICSS) of escalating opioid intake as well as withdrawal from opioid self-administration. Different groups of male Wistar rats self-administered oxycodone in either short- (1-hour sessions) or long- (11 or 12-hour sessions) access conditions. Subjects completed self-administration sessions five days per week, and this was followed by an intermittent, 60-hour discontinuation of access to oxycodone. As expected, subjects in the long-access group escalated their oxycodone intake while subjects in the short-access group did not escalate their oxycodone intake. Furthermore, escalation of intake increased in a stepwise pattern across successive weeks of oxycodone self-administration beginning with the first day following the 60-hour abstinence period. This latter finding indicates a facilitation of escalation of drug intake after intermittent abstinence, and if translated to humans, suggests that drug taking will be greater after a period of abstinence than the prior drug-taking episode. Moreover, escalated intake was associated with elevated ICSS thresholds, indicative of a diminished reward state and of a growing negative affective state that could be blocked via administration of a kappa-opioid receptor antagonist. Perhaps the most unexpected finding was that elevated ICSS thresholds began to normalize following the 60-hour abstinence period, and this normalization paradoxically facilitated escalation of oxycodone intake once long-access self-administration sessions resumed. In addition, ICSS thresholds could be normalized by providing access to a 1-hour oxycodone self-administration session. Dr. Nguyen also found that pretreatment with the phytocannabinoid, Δ9-tetrahydrocannabinol (THC), reduced oxycodone intake but did not alter the increase in reward threshold that was observed across sequential self-administration sessions, likely illustrating changes in the reinforcing efficacy of a unit dose of oxycodone. From these experiments, Dr. Nguyen and colleagues concluded that changes in brain reward function (i.e., ICSS thresholds) that occur during escalation of oxycodone intake were driven by an interaction between negative affective states and restoration of brain reward status during longer periods of abstinence. These results have clinically meaningful implications for adherence to prescription opioid medications in that early nonadherence could serve to increase prescription opioid intake following the period of nonadherence.
**Day-to-Day work**

*What is a rising issue in your area of expertise?*

I am not sure it is a rising issue, but more of an ongoing challenge in conducting research and developing interventions to treat substance use disorders. There is an increasing recognition that, to have the greatest impact on reducing the negative health and social consequences of problematic substance use and substance use disorders, we have to widen our approaches to include individual, interpersonal, provider, and system-level interventions. We are also moving towards recognizing multiple intersecting identities within individuals that contribute to risk and protective factors associated with substance use. I think this is an important shift and can improve our ability to more precisely target interventions and ultimately improve outcomes.

**Long-term career**

*You currently lead several SAMHSA-funded programs providing substance use, psychiatric treatment, HIV prevention, and housing services to underserved populations. How might your work interact with advocacy and policymaking?*

There are many ways that this work might be beneficial in addressing advocacy and policy issues. Our work directly increases access to substance use intervention, HIV prevention, and mental health treatment for populations that have not been prioritized. By demonstrating how a targeted approach to serving these populations reduces negative health and social outcomes related to HIV and substance use, policy makers may be able to see the benefit of making greater efforts to engage these populations.

**Work/life balance**

*Any tips? The work never ends, so what boundaries do you have in place to protect your personal time and your sanity?*

The work that we do is very important and is never ending. Learning how to step away from the work and protect the time you have for leisure and social activities is a crucial part of being successful in a career. It would be great if everyone learned how to do this early in their careers, but very few of us are able to navigate work/life balance well early on. Fortunately, it is never too late to recognize how taking time to recharge your batteries can actually make you better at the work you do. With many of us tied to our phones and other devices, it is very easy to blur the line between work time and personal time. When you are away from work, try to be really away from work. That means only checking emails and responding during times that you have decided you will work and letting things wait when you have decided that it is time to rest. Admittedly, this is something I am still working on. I think another important thing to remember is that it is OK to say no. There are so many opportunities for us to engage in work in very meaningful and impactful ways, but no one can do all of them if we want to do them well. I try to choose new projects and activities with these limitations in mind so that I can sometimes say “no” without guilt.

**Overcoming adversity**

*What do you think are the most common adversities that new and established professionals are facing in workplace? What is your advice/what are your potential solutions for overcome these adversities?*

I was a first generation college student. It seems like a small thing to some people, but not having a person in the family who had that college experience who could give advice and set expectations can make everything seem so much more overwhelming. Today, there are still people entering college for the first time who do not know how to navigate the process because no one in their circle has been there before. In my large extended family, I was the first to complete an advanced degree, and I am (so far) the only person in my family to pursue an academic career (university faculty). It doesn’t stop in the classrooms. These unknowns take place throughout the entire career. This is challenging, but it is possible to overcome by sticking with it and not being afraid to ask for help. At every stage of a career, there are different challenges. Perseverance is key. Having supportive mentors is vital. Recognizing that you are more than your last failure is liberating.

**Advice for Young Investigators**

*What advice would you give to a new grad student, a new postdoc, or a new investigator?*

There has been a lot of advice that has been important to me at different times. One that sticks with me no matter what stage of my career is to never be the one to tell myself, “No. You can’t do that.” Many people do not even attempt the next step because they think they are not smart enough, capable enough, or qualified enough. In reality you may be just the right person for that project, job, or promotion. I am not saying you should try to fly an airplane without taking some flying lessons, but do not get in your own way when pursuing the work that you are trained to do. I also encourage people to help others when they can and accept help when they need it. Collaboration and community help us all to be successful.
The CPDD Mentorship Program is an initiative run by the Early Career Member Committee (ECMC) as a way for more junior researchers (i.e. predoctoral fellows, postdoctoral fellows, medical residents) to connect with more senior researchers in their field to discuss topics such as career development, research ideas, and future goals. Mentor/mentee pairs are paired based on research interests, career field, or other requests by mentees. Mentees do not need to be CPDD members to participate. Typically, mentorship pairs connect in person at the CPDD conference, but for the 2020 and 2021 conferences, participants have met virtually. The 2021 CPDD Mentorship Program was a great success with 47 mentees paired with 36 mentors. Given the overwhelming mentee interest during last year and this year’s virtual conference, we asked mentors if they would be willing to provide mentorship for more than one mentee. Because of the generosity of mentors and their willingness to spend time mentoring, all mentees this year were assigned a mentor this year!

Prior to assigning mentors, mentees are encouraged to prepare their CV, as well as questions they would like to ask their mentor match. Once mentor/mentee matches are created, mentees are encouraged to initiate contact and scheduling the meeting, and to research their mentor’s work, if they are unfamiliar.

Results from a follow up survey of mentors/mentees indicated that the 2021 program was well received. All but one of the respondents reported meeting with their mentor/mentee pair via video chat. Most survey respondents (61%) reported spending 31 minutes to 1 hour with their mentor/mentee pair, 24% reported meeting for more than 1 hour, and 14% reported spending less than 30 minutes meeting. Nearly all (95%) of survey respondents thought their mentor/mentee was a good match. Some mentees reported concrete outcomes from the meeting, including plans for future networking, connecting about job/training opportunities, and progress in writing an article. Concrete outcomes from the meeting for mentors included planned future networking, idea generation, and ideas for collaboration and funding.

How likely are you to recommend participating in this program to others?

- Very Likely 57%
- Likely 33%
- Not Sure 10%

Taken together, these outcomes suggest that the Mentorship Program continues to be a successful ECMC initiative and is able to translate well to a virtual format. The ECMC is always looking for feedback on how to improve and expand this program. If there are Newsline readers interested in providing additional feedback, please don’t hesitate to reach out to Danielle Davis Danielle.davis@yale.edu or Maya Zegel mzegel@central.uh.edu who facilitated this year’s program.
Research Streamlining and Class-wide Scheduling of Synthetic Fentanyl Analogues

As the opioid crisis has morphed first from prescription opioids then to heroin and most recently to synthetic opioids and particularly fentanyl, the Drug Enforcement Administration and its allies in Congress are focused on putting all synthetic opioids, specifically fentanyl and its analogues in Schedule I of the Controlled Substances Act. Starting in February 2018, the DEA issued a two-year Temporary Scheduling Order that covered all synthetic opioids. That Order, which was originally scheduled to expire on February 6, 2020, was first renewed until May 2020. And on April 29 of this year, Congress extended the Temporary Scheduling Order again, this time until October 22, 2021.

Throughout this entire process, the College on Problems of Drug Dependence, in letters to the Senate Judiciary Committee and in testimony before two House Committees, has taken the following position on class-wide scheduling of fentanyl analogues, specifically stating: "We support efforts to give DEA authority to control the importation and distribution of synthetic fentanyl, but we also believe that any legislation to address this issue should include language reducing some of the barriers to research currently imposed by Schedule I licensing requirements and we are concerned about the unintended negative consequences of including such a broad range of substances in the scheduling language."

In an effort to come up with a long-term bipartisan solution to the fentanyl scheduling issue, on September 2, 2021, the Biden-Harris Administration released its "Recommendations on Class-wide Scheduling of Fentanyl-Related Substances." The Administration proposal would make permanent class-wide scheduling of fentanyl analogues but would include an expedited process dictated by the Secretary of Health and Human Services to remove those fentanyl compounds found not to be psychoactive or of limited abuse potential. To address sentencing concerns, the Biden-Harris proposal would "exclude those fentanyl-related substances which are not specifically listed in schedule I or II from certain quantity based mandatory minimum penalties associated with import and export offenses."

Most important for scientists conducting research on fentanyl-related substances, the Biden-Harris recommendations would make significant reforms to current DEA licensing requirements for all Schedule I compounds, not just fentanyl analogues but cannabis and all other schedule 1 compounds. The most prominent of these reforms is a provision that would create a more simplified process that would align Schedule I research registration more closely with the registration process for Schedule II substances. This new process would specifically apply if the research is either (a) funded—intramurally or by grant or contract—by HHS and the Veterans Administration, or (b) done under an Investigative New Drug (IND) exemption from FDA that is in effect. In addition, the proposal would not require separate registrations for additional researchers in the same institution.

CPDD, working with the Friends of the National Institute on Drug Abuse and the American Society for Pharmacology and Experimental Therapeutics (ASPET), have spent considerable time and effort formulating its own research streamlining proposals, briefing relevant Congressional Committees, and working with the Administration as it was conducting inter-agency negotiations with relevant agencies, including HHS and the Department of Justice and DEA. Most of our proposed reforms were incorporated into those recommendations advanced by the Biden-Harris Administration on September 2.

It's now up to Congress to review, adopt or amend the Administration's recommendations for fentanyl-related substances, with the goal of passing legislation prior to the October 22, 2021 deadline when the current Temporary Scheduling Order for Fentanyl Analogues expires.
Appropriations for the NIH and NIDA
On July 14, 2021, the House Appropriations Committee released their FY22 Labor HHS report ahead of full committee consideration of the bill tomorrow.

The House bill includes a total of $49 billion, an increase of $6.5 billion over Fiscal 2021, for the National Institutes of Health. Within that total, $3 billion is included for ARPA-H. For NIH base funding, the bill includes a $3.5 billion increase, which supports an increase of no less than 5 percent for each institute and Center.

For NIDA, the bill provides $1.860 billion, a $380 million increase over FY21 and $7.8 million more than the President’s budget. Within this amount, the Committee includes $405.4 million for the HEAL Initiative, $135.105 million above FY21 and the same as the President’s budget request. The Committee also includes an additional $196.3 million to support basic research related to opioids and other stimulants, as requested in the President’s budget.

Response to State-based Legislation Criminalizing Substance Use During Pregnancy
CPDD is working with a coalition of other science-based and public health organizations to address the increased number of state-based laws criminalizing or imposing other punitive approaches to substance use during pregnancy. In addition to CPDD, those organizations include the American Academy of Addiction Psychiatry (AAAP), American Psychiatric Association (APA), American Society of Addiction Medicine (ASAM), and the American Congress of Obstetricians and Gynecologists (ACOG).

All of our respective organizations support policies and programs that advance prevention and treatment of substance-related harm throughout a women’s reproductive years, with a particular focus on substance use during and following pregnancy. We also support policies that motivate women to adopt, or change, lifestyle behaviors to optimize their health and the health of their prospective babies. What is of concern to us is that public concern for preventing fetal harm has resulted in some states implementing punitive measures against pregnant or postpartum women.

BECOME A CPDD MEMBER
Membership applications are being accepted through October 15, 2021
Animals in Research Committee

The Committee is working on the 2022 Animal Forum submission. The tentative topic for next year’s Forum is “Animals in Research and the Hill,” with the goal of informing the membership of the political issues that affect addiction science from basic research to therapeutics discovery. We are in the process of identifying and contacting speakers for this submission.

The committee has prepared two Member Spotlight submissions: Dr. Jacques Nguyen from UC-San Diego (submitted by outgoing member Sally Huskinson), and Dr. Michelle Doyle, UTHSC-San Antonio (submitted by Rachel Altshuler).

The committee continues to work with the STAR (Supporting Truth about Animal Research) Coalition. This year’s L-HHS Appropriations Bill has Report language from the House of Representatives that includes strongly worded statements regarding primate research and alternatives to animal research—similar to the past two sessions of Congress. We are working with Senate staff to change the wording for the Report language. We also are still working on appointing a third STAR representative, with the goal of having one appointed by November 2021.

Awards Committee

Greetings from the CPDD Awards for Excellence Committee! Our committee is privileged to administer the Nathan B. Eddy Memorial Award, the Marian W. Fischman Lectureship Award for An Outstanding Woman Scientist, the CPDD Mentorship Award, the Joseph Cochin Young Investigator Award, the J. Michael Morrison Award and the Innovator Award. At this year’s conference, we honored the recipients of the 2020 Awards for Excellence, as well as the 2021 Joseph Cochin Young Investigator Award (the only award offered this year). Congratulations again to Dr. Cassandra Gipson-Reichardt, this year’s Cochin Award winner.

Our committee has enacted several changes to our Standard Operating Procedures that we’d like to highlight. First, in order to ensure a fair and balanced review process, we now require a minimum of 2 nominations for all awards, and we are working to implement strategies that will hopefully increase the number of nominations overall. Second, for the Mentorship Award, we are requesting that a separate list of trainees including categories of mentees (e.g., undergraduate, graduate, clinical, post-doc), duration/years of mentoring and type of mentorship (e.g., primary research mentor, committee member) be included with the nomination materials. The variability in how this information is provided in CVs has made it challenging to compare across nominees in previous years. Finally, in an effort to promote diversity, equity and inclusion, we will now track basic demographic information (age, gender, race/ethnicity) about each applicant across years.

Our committee would also like to remind the membership that we are committed to a confidential, yet transparent, review process. The committee members represent the diversity of interests of the College and are required to disclose actual or perceived conflicts of interest with any of the nominees--those with conflicts do not participate in the review process for a given award. The review process is similar to an NIH Study Section: committee members are provided the confidential materials for each nominee, they review the materials and provide preliminary scores, and those preliminary scores are used to guide the review discussion. Merit is the primary criterion, but diversity is encouraged and embraced.

I am honored to continue to serve as the Chair for the Awards for Excellence Committee and look forward to working with the Committee and the College to recognize the best and brightest of our members in the coming years. Please consider nominating deserving colleagues for one or more of the CPDD Awards for Excellence next year. Josh Lile

Code of Conduct Committee

The Code of Conduct Committee is responsible for receiving, reviewing, and processing reports of possible conduct violations that occur during the CPDD annual meetings. After reviewing a complaint, the committee discusses possible actions to be taken in response and provides a recommendation to the CPDD president, who then brings the issue to the EC. The committee chair is responsible for keeping complainants apprised of actions being taken.

At its meeting in June, 2020, the committee had recommended that a code of personal conduct that is more broadly applicable to behavior in general, and includes a commitment to anti-racist values, be drafted and perhaps added to the Bylaws. It was
suggested that members could be asked to acknowledge their acceptance of the code when paying annual dues. The CPDD Executive Committee indicated that the pertinent Bylaw as written is already sufficiently broad as to cover all CPDD activities.

As all committee members (except for Meg Haney and I) saw their terms end following the June 2021 meeting, and given the absence of reported incidents this year (a good thing given the task of this committee!), it was proposed that no new members be appointed. Meg and I will serve as Co-Chairs of the committee and CPDD members could be called upon to review any reports of conduct violations that might arise. It has been an honor serving as Chair of this committee and I thank everyone who participated in the drafting of the Code that is currently in use.

Communications Committee
The Communications Committee is charged with improving science communication as it relates to substance use research. The committee's ongoing oversight of CPDD publications is in line with this goal, including the Newsline electronic newsletter and the News and Views section of Drug and Alcohol Dependence. In addition, our committee is planning to reintroduce the Media Forum Symposium during the 2022 CPDD Annual Meeting. This symposium, which was canceled the last two years due to the COVID-19 pandemic, will profile accepted oral presentations in a "data blitz" format that serves to amplify cutting-edge research findings for science journalists and media outlets.

In addition, the committee is working on several new initiatives that can help to promote the communication of addiction science with the public, including increased utilization of social media platforms. Our work aims to educate the public on the best available evidence regarding substance use prevention, treatment, and harm reduction. In addition, a core focus of these communication efforts will be to reduce the stigma associated with drug use and to highlight the social justice issues that continue to impact people who use drugs disproportionately.

The Committee looks forward to the year ahead as we combine our shared interests and expertise in science communication to increase attention to substance use research within and outside of CPDD.

Early Career Member Committee
The CPDD Early Career Members Committee (ECMC), co-chaired by Lia Smith and Cecilia Bergeria, seeks to facilitate professional development and educational experiences for early career members of CPDD. ECMC serves current early career members of the College and those interested in becoming members including masters, doctoral, and postdoctoral level trainees, and early career professionals. Our newest program is the Early Career Research Presentation Competition. During this inaugural year, 12 finalists were selected for the competition based on abstract scores from the program committee. Fifty percent of all finalists represented researchers from underrepresented populations (NIH definition). Additionally, our finalists spanned across four areas of study including pre-doctoral preclinical research, post-doctoral preclinical research, pre-doctoral clinical research, and post-doctoral clinical research. Finalists were then invited to submit a 5-minute "Flash Talk" video, which presented the research from their abstract. Videos were assessed prior to the annual meeting according to a detailed rubric. During the 2021 annual meeting, each winner received recognition for their achievement and a cash prize of $250. Overall, the Early Career Research Presentation Competition was a success, and we look forward to continuing this initiative in the future.

ECMC has also continued to support several annual meeting initiatives, including the Annual Careers in Addiction Science Workshop, the Mentorship Program, and the Researcher Spotlight Series. This year, we sponsored the 7th Annual Careers in Addiction Science Workshop during the CPDD annual meeting. This workshop provides guidance and insight from leading addiction professionals across industry, government, academia, and non-profit sectors. We have also continued to support the ECMC Mentorship Program, which matches junior CPDD attendees with senior CPDD attendees for networking and mentorship opportunities. This year, we sought to provide participants with further resources to facilitate meaningful and productive experiences. Finally, we have continued to identify CPDD members to interview for our researcher spotlight series. Most recently, we highlighted Dr. Angela Heads. Dr. Heads is currently a CPDD board member and associate professor at the University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School.
As we look forward to the future, we plan to increase engagement among early career members of CPDD and to promote greater diversity within the ECMC committee. One of the ways in which we will be looking to engage early career members is through social media channels and the update of early career member resources on the CPDD website. We are passionate about supporting rising voices within CPDD and look forward to creating meaningful engagement with our members this year.

**Human Research Committee**

The committee presented its annual forum (Chairs: Victoria Votaw and Linda Cottler) at the CPDD 2021 meeting. The main theme for the forum was ethical challenges in addiction research during the COVID-19 pandemic. The forum covered topics such as virtual data collection, scientist burnout as well as challenges in addiction medicine publishing amid COVID-19 pandemic. The forum was well-attended, and the discussions were very insightful.

The committee presented a workshop (Chairs Alison Oliveto and Omayma Alshaarawy) at the CPDD 2021 meeting on ethical and practical considerations for clinical research with vulnerable populations in the age of electronic health records. After summarizing the historical context of privacy issues, survey results regarding experiences and perspectives of participants and researchers were presented. The panelists led an informative discussion and helped the relatively large audience with their questions.

**International Committee**

During this year’s CPDD meeting, the International Committee hosted its first CPDD workshop on June 23, Wednesday, 8:45-9:45. The well-attended workshop entitled, “Lost in Translation! How Can We Bridge the Research-To-Practice Gap Through International Collaboration?” was co-chaired by Committee members Francesca Filbey and Dace Svikis. The workshop included an expert panel of speakers, Dr. Steve Gust from NIDA, Dr. Steven Ondersma from Michigan State University and Dr. Deni Carise from Recovery Centers of America. The panelists discussed practical topics, challenges and solutions to international collaborations. Given the level of engagement and positive feedback from the workshop, the International Committee will continue to host the workshop annually.

The NIDA International Forum, which was canceled in 2020, was held virtually this year. Additionally, the NIDA International Forum/CPDD Workshop International Research Poster Session was held to accommodate time zone differences such that posters will be available continuously. The International Committee awarded the Best Poster Award to Dr. Enjeline Hanafi (Faculty of Medicine Universitas Indonesia) for her poster entitled, “Evidence of Telemedicine from a Developing Country During the COVID-19 pandemic: A Virtual Relapse Prevention Program Among a Clinical Sample of Substance-Use Disorder Patients”.

Finally, the International Committee awarded CPDD International Travel Awards to Dr. Suzaily Wahab (University Kebangsaan Malaysia Medical Centre, Malaysia), Dr. Gayatri Bhatia (All India Institute of Medical Sciences) and Dr. Afolabi Oyapero (Lagos State University College of Medicine).

**Long-Range Planning Committee**

The Long-Range Planning Committee has been hard at work developing new Mission and Vision Statements along with updating the organization’s Core Values and developing CPDD’s first long-range strategic plan. The new Mission and Vision Statements and the new Core Values can be found on the CPDD website. The updated strategic plan will be unveiled later this year. An intense amount of work has been completed by the committee in conjunction with the Board of Directors. CPDD has been listening to our members to help drive our organization into the future. Expect many more details in the coming months.

**Membership Committee**

As a member of CPDD and conference attendee, you may ask yourself what the membership committee does? The Membership and Credentialing committees had operated independently, but were merged within the past few years (now called the Membership Committee). As such, the Membership Committee now has two main functions. First, it attends to activities that address recruitment of new members and retention of current members. The Committee works toward the final goal of enlisting committed professionals with diverse backgrounds and interests in furthering basic and clinical science related to drug dependence. The Membership Committee reviews CPDD policies related to membership (such as membership levels, requirements and recruiting policies) and makes recommendations to the Board of Directors (BOD) on updating these policies, if deemed appropriate. The second function of the membership committee is to review and evaluate applications for membership in CPDD. The Committee
also is responsible for review and evaluation of requests for change in membership status. After reviewing each application, the Membership Committee makes recommendations to the BOD regarding approval of the membership application. Acceptance of recommendations requires voting by the BOD.

The Membership Committee is grateful to the CPDD members who have volunteered their time and effort to ensure that our college continues to grow and thrive. We spend time on our committee calls discussing how we can get the word out about CPDD membership and attract diverse voices to our college. In the coming months, we plan to work with the Underrepresented Populations Committee to combine efforts in order to recruit diverse members to our college. We want to ensure that we are not an exclusive club where membership is determined based on who you know, but rather, that we are a welcome college for those dedicated to the better understanding and treatment of drug dependence.

In addition to attracting and recruiting new members to the college, the committee is charged with reviewing applications and ensuring that potential new members meet the qualifications for each level of membership: Member in Training, Associate Member, Regular Member, and Fellows. In addition, the membership committee reviews requests for changes in membership status such as transitions from Associate to Regular Member or Regular Member to Fellow. Reviewed and approved applications are then submitted to the BOD twice a year for final approval. Recently, due to feedback from the CPDD membership and conference attendees interested in becoming members of the college, the process has been streamlined with help from the Parthenon Group to ensure that all of the required elements of the application are available for the committee to review. This assistance and preliminary review of submission applications has removed a major stumbling block for the committee. Further improvements in the process are being proposed that may allow for monthly review and approval of new applications. More to come, but the Membership Committee and the Parthenon Group are committed to improving the efficiency of membership application reviews and ensuring that reviews are thorough, fair, and rapid.

Program Committee
The Program Committee would like to thank all those who contributed to our meeting this year and helped us to make it a success. Most notably we’d like to thank our outgoing members Drs. Cassandra Gipson-Reichardt, Brian Kiluk, and Silvia Martins and welcome our incoming members Drs. Mance Buttram, Dustin Stairs, Denise Vidot, and Heather Ward to our committee. We have also welcomed Dr. Kevin Freeman to the team. Dr. Freeman will be shadowing the chair position leading up to the 2022 annual meeting and will assume the role of Chair of the Program Committee thereafter. Dr. Freeman has some exciting and innovative ideas for our meeting and we are excited to see how the meeting continues to thrive under his leadership.

This year was the first (and perhaps only?) year that we were able to plan from the beginning a fully virtual meeting experience and by all accounts it was a huge success. In addition to our traditional high-profile programming that included the Plenary session and addresses from NIDA director Dr. Volkow and NIAAA director Dr. Koob, we also had an invited guest for our Presidential session and several invited symposia. For the first time this year, we also developed a session devoted to our flagship journal Drug and Alcohol Dependence; this was highly attended and something we hope to continue providing to you in future conventions. We are grateful for the tremendous content that our attendees (you!) provided for us to organize into 3-4 concurrent virtual daily tracts, which resulted in a meeting that was innovative, provocative, and late-breaking. We saw strong adaptation to the virtual platform and were excited to see that our cherished in-person forums and workshops continued to be well-attended and to generate engaging discussions despite being a virtual experience. This was helped in part because of our integration of the program Gathertown into our convention program, which allowed us to provide a more familiar networking experience than our 2020 meeting.

We hope you were excited about the changes we made for our 2021 meeting and we want you to know that we aren’t done yet! Stay tuned for some new programming elements that we are working on now to implement in time for our 2022 meeting. We are continuing to learn from you and to rise to the new reality of digital and in-person convention programming. We ask for some patience- there are no roadmaps for how this might best be done- but assure you that we are working hard to develop a strong and engaging meeting experience that will be filled with rigorous research and rich networking opportunities. Stay tuned!

Rules Committee
Rules, Bylaws, legalistic details – sounds pretty boring, huh? Actually, it is anything but. The major responsibility of the Rules Committee is the care and feeding of the CPDD Bylaws. That
describes the nuts and bolts of the organization and, broadly, how it operates to carry out its mission. The Bylaws was adopted in 1980, shortly after CPDD was off-loaded as a committee from the National Academy of Sciences-National Research Council and became an independent organization. However, the Bylaws was meant to be, and has been, a living document, evolving as the needs and goals of the organization have changed. There have been 34 amendments to the Bylaws to date. Most of these have been relatively minor changes, like adding a new Standing Committee. However, some have been much more extensive, such as when CPDD became a credentialed membership organization. One such major revision came this past year as CPDD changed its organizational management model. The Rules Committee has traditionally been very small, often just the chair and perhaps one or two additional members. This has maintained easy continuity and most of the adopted amendments do not require extensive committee deliberations. When major changes are needed, the committee becomes functionally a lot larger by involvement of other groups in the organization. For organizational changes this last year the Rules Committee worked closely with the Executive Committee, the Long Range Planning Committee, the Parthenon Management Group, the then current Executive Officer, and the Director of the Executive Office. The Chair of the Rules Committee usually sits with Board at its regular meetings to monitor the need for potential Bylaws changes, interpret the Bylaws as needed and to serve informally as the Parliamentarian. A further explanation of the committee's SOPs can be found on the CPDD Website.

Travel Awards Committee
The CPDD Travel Awards Committee want to thank Aimee Campbell, Suzette Evans, Suzanne Nielsen, Kelly Peck and Brian Sherman for their service the past 3 years. We also want to welcome new committee members Alan Davis, Juhan Lee, Rachel Tomko, Matthew Ellis, Anne Skinstad, Chang-Guo Zhan, Shane Perrine, Jin Yoon, and Caroline Arout.

Fernando de Moura from Harvard Medical School was the recipient of this year's Holtzman Award, which recognizes outstanding early career contributions in pre-clinical research related to substance use disorders.

Laura Brandt from Columbia University and Irene Pericot-Valverde from Clemson University were the recipients of the FORCE (Female Opioid-addiction Research and Clinical Experts) travel awards this year. The FORCE travel awards honor female early career investigators conducting outstanding research on opioids and/or opioid use disorder.

An additional 95 junior scientists received travel awards for the 2021 CPDD meeting. This included 64 recipients of the CPDD Early Career Investigator Travel Award, 19 recipients of the NIDA Director’s Travel Award, and 12 recipients of the NIDA Women’s, Sex and Gender Travel Award. A full list of recipients for these awards can be found here: https://cpdd.org/cpdd-announced-2021-travel-award-recipients/.

Fingers crossed that we can all safely return to travel next year for the meeting, which will bring back the annual Brunch with Champions and awards reception to honor our outstanding early career scientists.

Underrepresented Populations Committee
The URPOP committee has been very busy this past year. We have developed and launched a diversity and inclusion survey. This survey is being conducted to better gauge the demographic composition of our society and ensure all communities are well represented. These data will be used to better assess which of CPDD’s efforts appear to be inclusivity enhancing, what may be counterproductive, and what might be tried in the future. We have analyzed data from the initial survey and presented these data at the annual meeting this past June.

As a committee we have also submitted commentaries to both Neuropsychopharmacology and Drug & Alcohol Dependence to address the need for increased diversity and inclusion in substance use research.


The URPOP Committee continues to support the career development of underrepresented racial/ethnic minority graduate students. This past year was an inaugural year for a special set of Primm Singleton awards. In collaboration with the Center for Technology & Behavioral Health at Dartmouth, we were able to support increased Primm Singleton awardees with a focus on the application of digital assessment or therapeutics to problems of substance use and related conditions. Please reach out and congratulate our 2021 Primm Singleton Award Winners:

- Emmanuel Alvarez, B.S.
- Mehreen Arif, M.P.H.
- Bryan Benitez, M.A.
- Whitney Cordoba-Grueso, M.D.
- Coralee Perez-Pedrogo, Ph.D.
- Edda Rodriguez, M.P.H.

If you have any questions, ideas, or would like to contribute to this effort, please contact Sherecce Fields, Chair of our Underrepresented Populations Committee, safields@tamu.edu!
Strength in numbers.

CPDD Membership

Application Deadline: October 15

LEARN MORE